In two phase 3 trials, oral IL-23 receptor inhibitor icotrokinra demonstrated superior efficacy and safety compared to the JAK inhibitor deucravacitinib in moderate-to-severe plaque psoriasis, marking a potential advancement in oral psoriasis therapies.